This randomized, open-label study is designed to evaluate the efficacy and safety of atezolizumab (anti-programmed death ligand 1 [PD-L1] antibody) plus bevacizumab versus sunitinib in participants with inoperable, locally advanced, or metastatic renal cell carcinoma (RCC) who have not received prior systemic active or experimental therapy, either in the adjuvant or metastatic setting.